StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Friday. Several other research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback